While compliance remains a major challenge for life sciences teams, most players in the sector continue to rely on infrastructure little suitable for the rate imposed by the rise of artificial intelligence and the cloud. It is this fracture that Ketryx wants to fill, an Austro-American company that develops a compliance platform powered by AI.
The Ketryx solution automation validation, traceability and regulatory workflows, including documentation in accordance with the requirements of the FDA and the European regulation on medical devices. According to the company, its customers find up to 90 % reduction in documentation time and marketing cycles more than ten times faster.
“I spent the last decade at the intersection of AI and life sciences, observing its evolution of an emerging tool for a critical application for patients. It is now time to accelerate adoption and ensure that AI is safe, reliable and adapted to regulated environments, “said Erez Kaminski, founder and managing director of Ketryx.
Already adopted by three of the five largest world companies in Medtech, as well as by several fortune companies 500, the platform stands out as a key infrastructure in the compliance of products powered by AI. Actors such as Deephealth, Heartflow and Aignostics already use it in their processes.
The company announces a lifting of 39 million euros in series B led by capital transformation. The operation brings the total funding to more than 55 million euros. Lightspeed Venture Partners, Mit’s E14 Fund, Ubiquity Ventures and 53 stations also participated. Founded by Erez Kaminski, Ketryx is based in Boston and Austria, and plans to accelerate its recruitments on the two sites.
